Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMEC/VI versus tiotropium in symptomatic COPD patients previously treated with tiotropium
NL-OMON38952Phase 3Withdrawn
- Sponsor
- GSK
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of umeclidinium, vilanterol and tiotropium in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Primary endpoint: Trough FEV1 on Treatment Day 85. Planned start Jun 2013; status: withdrawn.
02
Drugs
umeclidiniumvilanteroltiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON38952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38952.